83-2271-18　［受注停止］KRIBIOLISA Degarelix （Firmagon） ELISA 1 x 96 wells　KBI5008

特徴

• Description：Immunoassay for quantitative estimation of Degarelix in human serum, plasma and cell culture supernatant.
• Degarelix is used for the treatment of advanced prostate cancer.
• Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone （GnRH）receptors in the pituitary gland and blocks interaction with GnRH.
• This antagonism reduces luteinizing hormone （LH） and follicle-stimulating hormone （FSH） which ultimately causes testosterone suppression.
• Reduction in testosterone is important in treating men with advanced prostate cancer.
• FDA approved the same as "Firmagon" in December 2008.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The ELISA is a competitive immunoassay for the determination of Degarelix.
• A constant concentration of Degarelix coated on the microplate and varying concentration of standard or sample will compete for binding to gonadotropin-releasing hormone （GnRH） receptor.
• Detection antibody against GnRH conjugated to HRP is added to form a complex.
• The complex will produce a soluble colored product on substrate addition.
• The enzyme reaction is stopped by dispensing of Stop Solution into the wells.
• The optical density （OD） of the solution at 450 nm is inversely proportional to the amount of bound Degarelix present in standards or samples.